Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

@article{Coler2011DevelopmentAC,
  title={Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant},
  author={R. Coler and S. Bertholet and M. Moutaftsi and Jeff Guderian and H. Windish and S. Baldwin and Elsa M. Laughlin and M. S. Duthie and Christopher B Fox and D. Carter and M. Friede and T. Vedvick and S. Reed},
  journal={PLoS ONE},
  year={2011},
  volume={6}
}
  • R. Coler, S. Bertholet, +10 authors S. Reed
  • Published 2011
  • Biology, Medicine
  • PLoS ONE
    • Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human… CONTINUE READING
    View PDF
    240 Citations
    Highly Influencial Citations
    12
    Background Citations
    80
    Methods Citations
    23
    Results Citations
    2

    Paper Mentions

    Interventional Clinical Trial
    Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
    The clinical trial phase 2b is designed to assess the safety and the specific immune response of the active ingredient (protein + adjuvant) in healthy and then in infected school… Expand
    ConditionsSchistosomiasis
    InterventionBiological, Drug
    Oswaldo Cruz Foundation
    December 2018 - January 2020
    Interventional Clinical Trial
    Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions
    The clinical trial phase 2a is designed to assess the safety of the active ingredient (protein + adjuvant) and secondarily its immunogenicity in healthy male adults from 18 to 49… Expand
    ConditionsSchistosomiasis
    InterventionBiological, Drug
    Oswaldo Cruz Foundation
    December 2016 - June 2017
    240 Citations
    Citation Type

    Citation Type

    Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
    • 37
    • PDF
    Characterization of the Structure and Immunostimulatory Activity of a Vaccine Adjuvant, De-O-Acylated Lipooligosaccharide
    • 16
    • PDF
    The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age
    • 12
    Synthesis and immunological evaluation of a low molecular weight saccharide with TLR-4 agonist activity.
    • PDF
    Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
    • 37
    • PDF
    Adjuvant Activity of Naturally Occurring Monophosphoryl Lipopolysaccharide Preparations from Mucosa-Associated Bacteria
    • 18
    • PDF
    A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo
    • 58
    Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.
    • 14
    The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction
    • 26
    • PDF
    Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses
    • 15
    • PDF

    References

    SHOWING 1-10 OF 48 REFERENCES
    The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
    • 696
    Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
    • 227
    Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.
    • 98
    Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A*
    • 79
    • Highly Influential
    • PDF
    Bacterial lipopolysaccharides and innate immunity.
    • 561
    Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.
    • 55
    Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
    • 867
    • PDF
    Structural Regions of MD-2 That Determine the Agonist-Antagonist Activity of Lipid IVa*
    • 63
    • PDF
    Adjuvants--a balance between toxicity and adjuvanticity.
    • 540
    Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis1
    • 128
    • PDF